WINSUN BIO(BJ:839729)2024-09-13 09:05Group 1: Investor Relations Activity Overview - The investor relations activity was conducted online on September 12, 2024, from 15:30 to 16:30 [2] - Participants included investors engaging through the "Investor Relations Interactive Platform" [2] - Company representatives included General Manager Wu Feng, Deputy General Manager and CFO Li Qiuhong, and Secretary of the Board Lin Jianxin [2] Group 2: Financial Performance and Challenges - In the first half of 2024, the company reported revenue of 119.1762 million yuan, a year-on-year decline of 21.96% [5] - Net profit for the same period was 15.5339 million yuan, down 60.96%, primarily due to decreased income from piglets and changes in product sales structure [5] - The gross margin for pig vaccines was 78.64%, a decrease of 0.75 percentage points year-on-year, while the overall gross margin was 58.69%, down 3.42 percentage points [5] Group 3: Strategic Responses and Future Plans - The company is optimizing its organizational structure to adapt to the trend of large-scale farming, including splitting the piglet business into two regional divisions [5] - A "cost reduction and efficiency enhancement" task force has been established to improve profitability across the business chain [5] - The company plans to increase R&D investment and enhance product quality to maintain competitive advantages in the vaccine market [7] - Future challenges include industry overcapacity and intensified competition, with plans to focus on innovation and service quality to mitigate risks [7]